Allele-specific transcription of the PAI-1 gene in human astrocytes

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 998-1008

  Hultman, Karin ^a,b   Tjärnlund Wolf, Anna ^a,b   Odeberg, Jacob ^c   Eriksson, Per ^c   Jern, Christina ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HaploChIP; Human astrocytes; Plasminogen activator inhibitor type 1; Transcriptional activity

Indexed keywords

NUCLEAR PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR ELF 1; TRANSCRIPTION FACTOR ELK 1;

ALLELE; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CHROMATIN IMMUNOPRECIPITATION; DNA SEQUENCE; GEL MOBILITY SHIFT ASSAY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INDEL MUTATION; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA INTERACTION;

ALLELES; ASTROCYTES; BINDING SITES; BRAIN ISCHEMIA; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETS-DOMAIN PROTEIN ELK-1; HAPLOTYPES; HUMANS; INDEL MUTATION; INTERFERON REGULATORY FACTOR-2; NUCLEAR PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RNA POLYMERASE II; STROKE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78149487252     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-04-0243     Document Type: Article

References (28)

1. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
2. Boekholdt SM, Bijsterveld NR, Moons AH, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104: 3063-3068.
3. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997; 17: 851-858.
4. Anderson JL, Muhlestein JB, Habashi J, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999; 34: 1778-1783.
5. Grubic N, Stegnar M, Peternel P, et al. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 1996; 84: 431-443. (Pubitemid 27033603)
6. Abboud N, Ghazouani L, Saidi S, et al. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study. Genet Test Mol Biomarkers 2010; 14: 23-27.
7. Verschuur M, Jellema A, Bladbjerg EM, et al. The plasminogen activator inhibitor- 1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis 2005; 181: 275-284.
8. Haselbauer A, Haberbosch W, Tillmanns H, et al. The impact of the PAI-1 A((-844))G promoter polymorphism on the risk and extent of coronary heart disease. Thromb Haemost 2002; 88: 697-698. (Pubitemid 35174022)
9. Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
10. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
11. McCormack LJ, Semple JI, Stickland MH, et al. The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells. Thromb Res 1998; 92: 199-206.
12. Bentley P, Peck G, Smeeth L, et al. Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS One 2010; 5: e9136.
13. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101: 67-70.
14. Gravanis I, Tsirka SE. Tissue plasminogen activator and glial function. Glia 2005; 49: 177-183.
15. Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. Biochem J 1988; 251: 327-332.
16. Calabresi P, Napolitano M, Centonze D, et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 2000; 12: 1002-1012.
17. Tsirka SE, Rogove AD, Bugge TH, et al. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17: 543-552.
18. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-1540.
19. Yang D, Nemkul N, Shereen A, et al. Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci 2009; 29: 8669-8674.
20. Nagai N, De Mol M, Lijnen HR, et al. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99: 2440-2444.
21. Docagne F, Nicole O, Gabriel C, et al. Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol Cell Neurosci 2002; 21: 634-644.
22. Knight JC, Keating BJ, Rockett KA, et al. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 2003; 33: 469-475.
23. Weeks JR, Hardin SE, Shen J, et al. Locus-specific variation in phosphorylation state of RNA polymerase II in vivo: correlations with gene activity and transcript processing. Genes Dev 1993; 7: 2329-2344.
24. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
25. Wolf AT, Medcalf RL, Jern C. The t-PA -7351C>T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid. Blood 2005; 105: 1060-1067.
26. Hultman K BF, Nilsson M, Wilhelmsson U, et al. Expression of PAI-1 and PN-1 in human astrocytes; response to injury-related factors. J Neurosci Res 2010; 88: 2441-2449.
27. Morange PE, Saut N, Alessi MC, et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007; 27: 2250-2257.
28. Buchwalter G, Gross C, Wasylyk B. Ets ternary complex transcription factors. Gene 2004; 324: 1-14.